Base Editing, the Story So Far

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Subsection - Oncology

Essential DMPK Strategies for IND Success

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Gene editing technologies have been evolving since CRISPR was first commercialised in early 2012. The recent emergence of CRISPR base editing platforms has attracted attention in the cell and gene therapy fields. This is a gene-editing technology that could drive the evolution of new therapeutic applications.
Kevin Hemphill at Horizon Discovery touches upon the potential therapeutic applications of base editing and explains why there is so much hype around this latest incarnation of CRISPR-based gene editing.